

**Prolia (denosumab) Prior Authorization form (Drugs Administered in Office), fax requests to 844-639-7906**

Please complete the form by providing all of the following information. Failure to fill out this form in its entirety may delay the review process. To review the Clinical Medical Policies, please visit our website at <https://www.nhpri.org/Providers/ClinicalMedicalPolicies.aspx>

**MEMBER INFORMATION**

Member's Name:	Member's ID #:	Member's DOB:
Member Phone Number:	Member Address:	Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female <input type="checkbox"/> Unknown Primary Language: <input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other:

**REQUESTING PROVIDER INFORMATION**

Provider's Name:	Provider's Phone #:	Provider's Fax #:
Date of Request:	Provider's NPI #:	Provider's Contact Name and Phone:

**SERVICING PROVIDER INFORMATION (Must be filled out appropriately to ensure claim adjudication)**
**HOW WILL MEDICATION BE OBTAINED:**

☐ Drop Ship from Specialty Pharmacy: \_\_\_\_\_ and NPI \_\_\_\_\_

☐ If Buy & Bill: Specify Provider/ Facility: \_\_\_\_\_ and NPI \_\_\_\_\_  
Servicing Provider Fax#: \_\_\_\_\_

**CLINICAL INFORMATION**

Requested J-Code:	Requested CPT code(s):	<input type="checkbox"/> Initial Request <input type="checkbox"/> Continuation of therapy Request
Drug Name& strength:	Date(s) of Service Requested:	
Directions:	# of units:	
ICD 10 Codes:		

Clinical Assessment (provide all required information and clinical documents)	YES	NO
Is Prolia (denosumab) being used for the treatment of osteoporosis in postmenopausal women at high risk for fracture?	<input type="checkbox"/>	<input type="checkbox"/>
Is Prolia (denosumab) being used for treatment of bone loss in women receiving aromatase inhibitor therapy for breast cancer?	<input type="checkbox"/>	<input type="checkbox"/>
Is Prolia (denosumab) being used for the treatment of bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer?	<input type="checkbox"/>	<input type="checkbox"/>
Patient has had an inadequate response to alendronate and ibandronate as evidenced by a T score of under -2.0 ( please include clinical documentation)	<input type="checkbox"/>	<input type="checkbox"/>
Does the patient have a documented intolerance or contraindication to both alendronate and ibandronate?	<input type="checkbox"/>	<input type="checkbox"/>

**NOTE: THIS FORM MUST BE SIGNED BY A PHYSICIAN**

Signature of Requesting Provider:	Date:
-----------------------------------	-------

*Authorization is not a guarantee of payment. Member must be eligible at time of service.*